We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    ZN-c5
Previous Study | Return to List | Next Study

A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04852419
Recruitment Status : Completed
First Posted : April 21, 2021
Last Update Posted : August 11, 2022
Sponsor:
Information provided by (Responsible Party):
Zentera Therapeutics HK Limited

Tracking Information
First Submitted Date  ICMJE April 11, 2021
First Posted Date  ICMJE April 21, 2021
Last Update Posted Date August 11, 2022
Actual Study Start Date  ICMJE May 31, 2021
Actual Primary Completion Date June 23, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 15, 2021)
  • Observed Dose Limited Toxicities (DLTs) in safety lead in phase [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Safety lead in phase at dose of 50 mg QD: Determine a tolerated dose for ZN-c5 in monotherapy
  • Incidence of treatment-emergent adverse events [ Time Frame: until 30 days after the last dose of study drug ]
    Investigate the safety and tolerability of dose of 50 mg QD of ZN-c5
  • Incidence of treatment-emergent adverse events [ Time Frame: until 30 days after the last dose of study drug ]
    Investigate the safety and tolerability of dose of 150 mg QD of ZN-c5
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 15, 2021)
  • CBR (CR [+ PR] + SD ≥ 24 weeks). [ Time Frame: 2 year ]
    Investigate the preliminary antitumor activity (clinical benefit rate [CBR]) for ZN-c5 as a monotherapy using Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) as assessed by investigators.
  • bjective Response Rate (ORR) [ Time Frame: 2 year ]
    Assess preliminary antitumor activity of ZN-c5 alone by Objective Response Rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) as assessed by investigators.
  • Duration of Response (DOR) [ Time Frame: 2 year ]
    Assess preliminary antitumor activity of ZN-c5 alone by Duration of Response (DOR) using Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) as assessed by investigators.
  • Progression-Free Survival (PFS) [ Time Frame: 2 year ]
    Assess preliminary antitumor activity of ZN-c5 alone by Progression-Free Survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) as assessed by investigators.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS
Official Title  ICMJE A PHASE 1B STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF ZN-C5 IN CHINESE SUBJECTS WITH ADVANCED BREAST CANCER
Brief Summary The aim of this phase 1b study in Chinese patients with ER+/Her2- advanced breast cancer is to evaluate the safety and tolerability of ZN-c5 at dose of 50 mg and 150 mg QD well tolerance established in the previous oversea study in non-Chinese patients.
Detailed Description Hormone receptor-positive, HER2-negative breast cancer is the most common subset of breast cancer. The estrogen receptor (ER) in these patients is a key driver of disease progression, and the primary reason for relapse in these patients is that endocrine therapies are only partially effective, typically causing cell cycle arrest rather than cell death. As a result, secondary resistance to endocrine therapy is a major clinical challenge. ZN-c5 is a novel and potent ZN-c5 is a novel and potent selective estrogen receptor degrader with oral bioavailability and strong activity in estrogen-dependent and tamoxifen-resistant tumor models.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Neoplasms
Intervention  ICMJE Drug: ZN-c5
ZN-c5
Study Arms  ICMJE
  • Experimental: ZN-c5 50mg QD dose cohort
    Phase 1b trial of monotherapy cohort with ZN-c5 as single agent will be evaluated with ZN-c5 50 mg administered orally, once daily. Safety lead in phase will be applied.
    Intervention: Drug: ZN-c5
  • Experimental: Zn-c5 150mg QD dose cohort
    Once safety and tolerability are established in ZN-c5 150 mg Dose QD in Chinese population, then it is possible to initiate the second monotherapy cohort with 150 mg QD or alternative dose well established in oversea population for preliminary efficacy and safety.
    Intervention: Drug: ZN-c5
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 10, 2022)
12
Original Estimated Enrollment  ICMJE
 (submitted: April 15, 2021)
24
Actual Study Completion Date  ICMJE June 23, 2022
Actual Primary Completion Date June 23, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female
  • Age ≥ 18 years
  • Menopausal Status [Female subjects]
  • Histologically or cytologically confirmed diagnosis of advanced adenocarcinoma of the breast, not amenable to any potential curative intervention
  • Estrogen Receptor (ER) positive disease
  • Human Epidermal Growth Factor Receptor 2 (HER2) negative disease
  • Refractory to or intolerant of established therapy(ies) known to provide clinical benefit for their malignancy
  • Prior Hormonal Therapy:
  • Documented prior response to endocrine therapy for advanced or metastatic disease (SD, PR, or CR) lasting > 6 months24 weeks or disease recurrence after at least 24 months of adjuvant endocrine treatment.
  • Prior Chemotherapy: Up to 2 prior lines of chemotherapy for the treatment of advanced breast cancer
  • Prior treatment with a CDK4/6 inhibitor is allowed
  • Evaluable or measurable disease per RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1
  • All acute toxic effects of any prior anti-tumor therapy resolved to Grade ≤ 1 or baseline (with the exception of alopecia [any grade permitted])
  • Adequate organ function
  • [Premenopausal and perimenopausal female subjects]: Negative serum pregnancy test
  • Male and female subjects of childbearing potential or partners of subjects who engage in intercourse must agree to use protocol specified method(s) of contraception.

Exclusion Criteria:

  • Any of the following within the specified window prior to the first dose of study drug
  • Prior hematopoietic stem cell or bone marrow transplantation
  • Prior radiotherapy to > 25% of bone marrow
  • Brain metastases that require immediate treatment or are clinically or radiologically unstable (i.e., have been stable for < 1 month). If receiving steroids, subjects must be receiving a stable to decreasing corticosteroid dose during at least 1 week before enrollment.
  • Leptomeningeal disease that requires or is anticipated to require immediate treatment.
  • Presence of life-threatening metastatic visceral disease or symptomatic pulmonary lymphangitic spread
  • Other known active cancer(s) likely to require treatment in the next year that would impact the assessment of any study endpoints
  • [Female subjects]: Pregnant or breast-feeding
  • Unexplained symptomatic endometrial disorders (including, but not limited to endometrial hyperplasia, dysfunctional uterine bleeding, or cysts)
  • Impairment of gastrointestinal (GI) absorption for oral medications
  • Nausea, vomiting, or diarrhea > Grade 1
  • Myocardial infarction, symptomatic congestive heart failure (NYHA > Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months
  • QTc interval > 480 msec (based on the mean value of the triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome or history of Torsade de Pointes
  • Concurrent use of food or drugs known to be moderate or strong CYP3A or CYP2C9 inducers and moderate or strong CYP3A4 or CYP2C9 inhibitors.
  • Positive serum virological tests (HBsAg, HCV-AB, HIV-AB, TP-AB) at screening stage will be excluded.
  • Any clinically significant disorder, condition, or disease that, in the opinion of the Investigator or Medical Monitor would pose a risk to subject safety or interfere with the study evaluations, procedures, or completion
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04852419
Other Study ID Numbers  ICMJE c5ZTCN100
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Current Responsible Party Zentera Therapeutics HK Limited
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Zentera Therapeutics HK Limited
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Zentera Therapeutics HK Limited
Verification Date August 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP